Background. Gram-positive pathogens can cause serious infections in neutropenic patients with cancer, and vancomycin therapy is often initiated empirically. Linezolid may offer an option for these patients.
Immediate empirical antibiotic therapy is the standard of care for patients with febrile neutropenia [1] , but no single regimen is ideal. Vancomycin is an option for selected patients, such as those with serious catheterrelated infections or colonization with methicillin-resistant Staphylococcus aureus (MRSA) [1] . The rationale is based on the shift in causative pathogens, with grampositive bacteria accounting for 60%-70% of bacterial pathogens isolated from febrile neutropenic patients [1, 2] , and an increasing prevalence of MRSA. The role of vancomycin is debatable, because it has not been shown to reduce the overall mortality of patients with grampositive bacterial infections, with the possible exception of viridans streptococcal infections [3, 4] . Additional disadvantages include vancomycin resistance [5, 6] , enhanced aminoglycoside nephrotoxicity, and lack of orally bioavailable formulation.
Linezolid, a novel oxazolidinone antimicrobial agent, is an alternative because of its activity against grampositive bacteria [7] , including bactericidal activity against streptococci [8] . The clinical efficacy and safety of linezolid were comparable to those of vancomycin in randomized studies of nonneutropenic patients with gram-positive bacterial infections, including nosocomial pneumonia [9, 10] , complicated skin and softtissue infections [11] , and MRSA infections [12, 13] .
We hypothesized that linezolid would be as safe and effective as vancomycin in febrile neutropenic patients with cancer. To test this hypothesis, we conducted a randomized, double-blind, multicenter, phase 3 equivalence study involving patients eligible for vancomycin therapy because of proven or suspected gram-positive bacterial infection.
PATIENTS AND METHODS
Eligibility criteria. Hospitalized febrile adults (age, у13 years; weight, 140 kg) with cancer were eligible for the study if they had proven or suspected gram-positive bacterial infection, as determined on the basis of suspected catheter infection, severe mucositis or dermatitis, colonization with methicillinresistant staphylococci or drug-resistant Streptococcus pneumoniae, hypotension, or failure of empirical broad-spectrum antibiotic therapy within 72 h before enrollment. Fever was defined as a single oral temperature of 138.9ЊC or axillary temperature of 138.1ЊC, or as a temperature for у1 h of у38.6ЊC orally or у37.8ЊC axillary. Patients were required to have chemotherapy-induced neutropenia (absolute neutrophil count, р500 cells/mm 3 ) or expected to develop neutropenia within 48 h. Females of child-bearing potential were required to have a negative pregnancy test result, to take contraceptive precautions, and to refrain from breast-feeding. Exclusion criteria were pathogen resistance to the study drugs; fever of noninfectious etiology; neutropenia unassociated with high risk of bacterial infection; allogenic bone marrow transplantation р4 weeks earlier; death likely to occur before posttherapy evaluation; clinical improvement р72 h after commencement of broad-spectrum antibiotic; exposure to vancomycin therapy within 1 week before enrollment; endocarditis, osteomyelitis, or CNS infection; pheochromocytoma, carcinoid syndrome, uncontrolled hypertension, or untreated hyperthyroidism; or allergy to study drugs.
The study was approved by investigators' institutional review boards. Patients were required to provide valid written informed consent.
Interventions. Eligible patients were randomly assigned in a 1:1 ratio to receive linezolid (600 mg every 12 h) or vancomycin (1 g every 12 h), each administered intravenously for 10-28 days. To maintain blinding, a research pharmacist prepared study medications; an unblinded coinvestigator monitored vancomycin or serum creatinine levels in accordance with local practice.
Patients were not to receive other potentially effective antibiotics with activity against gram-positive pathogens unless the study drug was ineffective. Concomitant therapy was allowed in accordance with the usual standard of care.
Assessment of response and safety. Patients were assessed at enrollment (baseline), during therapy, at the end of therapy, and at 7 days after completion of therapy (test of cure [TOC] ).
Temperature was measured daily; other vital signs were measured weekly. Blood samples were drawn for duplicate cultures at baseline; if the results were positive at baseline, samples were also obtained at 48 h and at the TOC examination; and if the results were positive at 48 h, samples were obtained at 96 h. Infection site cultures and bacterial susceptibility tests were performed at a central laboratory at baseline and, if possible, at the end of therapy and at the TOC assessment. Hematologic and serum chemistry studies were performed at baseline, at predetermined intervals during therapy, at the end of therapy, and at the TOC assessment. Urinalysis was performed at baseline and at the TOC assessment.
Patients were evaluated for response at the end of therapy and at the TOC assessment. Clinical success was defined as cure (defervescence and resolution of signs and symptoms of infection) or improvement (defervescence and improvement of signs and symptoms of infection). Defervescence was defined as maximum oral temperature of р37.5ЊC or axillary temperature of р36.7ЊC on 3 consecutive days. Failure was defined as persistence or progression of clinical signs and symptoms of infection or development of new findings. An indeterminate outcome was defined as an inability to make an assessment.
Microbiologic outcome was assessed as success (documented eradication, presumed eradication, or colonization), failure (documented persistence, presumed persistence, or superinfection), indeterminate, or missing. Data on gram-negative pathogens were not collected.
Investigators monitored patients for adverse events through the TOC assessment. Because of anticipated morbidity and mortality, an independent data-monitoring committee was established to prospectively assess safety data and the potential need for study modification.
Data analysis. Three hundred clinically evaluable patients (150 per group) were required to determine equivalence (15% margin) between groups based on a 2-sided test level of .05 and statistical power of 90%, assuming a clinical cure rate of 80% [14, 15] . The intent-to-treat (ITT) population comprised patients who received at least 1 dose of study drug. The modified ITT (MITT) subset comprised ITT patients infected with gram-positive pathogens at baseline. The clinically evaluable (CE) subset comprised ITT patients who received sufficient therapy (i.e., у7 days for outcome of success or у3 days for outcome of failure), received у80% of intended therapy, and underwent postbaseline assessment; patients were nonevaluable if they received potentially effective antibiotics for intercurrent illness. The microbiologically evaluable (ME) subset comprised CE patients infected with baseline gram-positive pathogens susceptible to both study drugs.
Groups were compared for demographic characteristics using analysis of variance for continuous variables and the x 2 test for 2-way contingency tables for categorical variables. The primary a Missing or indeterminate outcome. b Evaluable patients received sufficient therapy (у7 days for outcome of success or у3 days for outcome of failure), received у80% of intended therapy, and completed a postbaseline assessment; patients were considered to be nonevaluable if they received a potentially effective antimicrobial for intercurrent illness. ITT, intent-to-treat. efficacy end point was clinical outcome at the TOC assessment. Secondary efficacy end points were defervescence rate, time to defervescence, resolution of neutropenia, time to resolution of neutropenia, microbiologic outcome, and mortality rate. Rates of efficacy outcomes and adverse events were compared between groups using the x 2 test of homogeneity of proportions; 95% CIs were calculated for between-group differences in rates of efficacy end points and were based on the normal approximation to the binomial distribution. Kaplan-Meier estimates were obtained for time-to-event end points, and log-rank tests were used to compare time-to-event end points between groups. All statistical analyses were 2-tailed. P values р.05 were considered to be statistically significant.
RESULTS
Six hundred eleven patients were enrolled from November 2000 through May 2002 by 58 investigators in Australia, Austria, Belgium, Croatia, France, Germany, Greece, Italy, Poland, Russia, Slovenia, South Africa, Spain, and Switzerland (figure 1). Six patients did not receive the study drug. Two hundred two patients were not clinically evaluable because they had fever of uncertain origin and received additional antiviral, antiparasitic, or antifungal drugs (56 subjects in the linezolid group and 57 subjects in the vancomycin group); received insufficient study drug (21 and 27 subjects, respectively); did not undergo a postbaseline assessment (18 and 26 subjects, respectively); received concomitant anti-infectives for intercurrent illness (10 and 12 subjects, respectively); did not comply with drug regimen (1 and 2 subjects, respectively); or were not eligible (1 and 0 subjects, respectively). Some patients were not evaluable for 11 reason.
Baseline characteristics were similar between groups ( 3 if it was expected to decrease to !500 cells/mm 3 within 48 h. "Not reported" includes patients in whom the absolute neutrophil count may not have been determined because their WBC count was less than their institutions' limit for differentiation. Data were available for 239 patients in the linezolid group and 243 patients in the vancomycin group. Patients for whom data were not reported were excluded from calculation of percentages.
c Duration of neutropenia before receipt of the first dose was determined for 297 patients in the linezolid group and for 293 patients in the vancomycin group. d Some patients were infected with 11 pathogen. The most common streptococci were Streptococcus mitis (2 patients in the linezolid group and 5 in the vancomycin group) and Streptococcus oralis (2 and 3 patients, respectively). The most common "other" staphylococci were Staphylooccus hominis (4 and 3 patients, respectively) and Staphylococcus warneri (3 and 1 patients, respectively).
principally because their WBC counts were so low that the institutions did not require or were not capable of performing differentiation. All but 2 patients, both in the vancomycin group, received anti-infective medication before enrollment or starting on day 1 ( [63%] of 51 and 24 [56%] of 43 patients, respectively; P p ). There were no differences in eradication rates for indi-.50 vidual pathogens, including MRSA, except for Enterococcus faecium, which was eradicated from 4 (100%) of 4 linezolid-treated patients and 2 (29%) of 7 vancomycin-treated patients (P p ). A respiratory isolate of E. faecalis developed resistance to .02 vancomycin during treatment, and vancomycin-resistant E. faecium was isolated from a blood sample from another vancomycin-treated patient who had negative baseline culture results. Linezolid resistance was not observed.
Mortality. Mortality rates at 16 days after completion of therapy were similar between groups in all study populations. In the ITT population, 17 (5.6%) of 304 linezolid-treated patients died, compared with 23 (7.6%) of 301 vancomycintreated patients ( ). In the linezolid group, the most P p .31 common causes of death were septic shock or sepsis (8 patients), pneumonia or respiratory failure (3 patients each), and cerebral hemorrhage or multiple-organ failure (2 patients each). In the vancomycin group, the most common causes were progression of malignancy (5 patients); pneumonia, septic shock or sepsis, and renal failure or increased serum creatinine level (4 patients each); respiratory failure or cardiopulmonary arrest (3 patients each); and dyspnea or multiple-organ failure (2 patients each). Some patients had 11 potential cause of death.
Safety. All patients were analyzed for adverse events, except for 1 in each group whose adverse events were not recorded. The distribution of all adverse events, including those unrelated to treatment, was similar between groups (table 5) . Drug-related adverse events occurred more frequently in the vancomycin group (24.0% vs. 17.2%;
). Renal failure oc-P p .04 curred more frequently in the vancomycin group for drugrelated episodes (2.3% vs. 0.3%;
) and all-causality P p .04 episodes (5.0% vs. 1.7%;
). P p .02 Most drug-related adverse events were mild or moderate in Table 4 . Microbiologic outcome at 7 days after the completion of therapy (i.e., severity; serious drug-related adverse events occurred in 3 linezolid-treated patients and 12 vancomycin-treated patients. The distribution of treatment discontinuations associated with drug-related adverse events was similar between groups (linezolid group, 3.6%; vancomycin group, 5.0%;
). Death P p .41 was probably or possibly related to study drug for 1 patient in each group. The causes of death were septic shock, dermatitis, and skin disorder in the linezolid-treated patient and anuria and acute renal failure in the vancomycin-treated patient.
There were no between-group differences in hematologic events in the ITT population. The incidence of any bleeding complication, including episodes unrelated to treatment, was similar between groups (linezolid group, 34 [11.2%] ). No bleed-P 1 .1 ing complications were considered to be related to study drugs.
There were no between-group differences in mean hematologic parameters, although analysis of mean WBC and neutrophil counts revealed trends favoring vancomycin (table 6) . Post-hoc Kaplan-Meier analysis of time to absolute neutrophil count recovery favored vancomycin in the MITT subset ( , by the log rank test) and the microbiologically ev-P p .02 aluable subset ( ), but not for patients with fever of P p .01 uncertain origin ( ; figure 2) . Mean platelet counts re-P p .45 mained nearly identical between groups throughout the study (table 6) , as did time to recovery of the platelet count (P p ; figure 3 ). Abnormal platelet counts (i.e., !75% of the lower .80 limit of normal or, if low at baseline, !75% of the baseline value) occurred in 162 (53.5%) of 303 linezolid-treated patients and in 169 (56.5%) of 299 vancomycin-treated patients.
The between-group distribution was similar for abnormal hemoglobin values ( 
DISCUSSION
This randomized, double-blind, multicenter, equivalence study demonstrates that linezolid is associated with efficacy equivalent to that of vancomycin in febrile neutropenic patients. Results measured by the primary end point (clinical success) and secondary efficacy end points (microbiologic outcome and mortality rate) were similar in linezolid-and vancomycin-treated patients.
Others have reported that addition of an antistaphylococcal antibiotic to broad-spectrum therapy did not improve outcome in febrile neutropenic patients. Between-study similarities in methods and patients invite comparison, although some end points differed. Cometta et al. [16] reported that 165 patients randomly assigned to receive vancomycin or placebo had similar median times to defervescence (3.5 vs. 4.3 days; ) P p .75 and mortality rates (5% vs. 10%;
). Ramphal et al.
[17] P p .23 reported that 127 patients randomly assigned to receive vancomycin or no vancomycin had similar defervescence rates at 96 h (61% vs. 56%) and mortality rates (11% vs. 10%). Erjavec et al. [18] reported that 114 patients randomly assigned to receive teicoplanin or placebo had similar defervescence rates at 72 h (45% vs. 47%) and mortality rates (11% vs. 7%). The major difference between these studies and our study was sample size. Although the first and largest study did not meet its target sample size of 226 assessable patients, Cometta et al. [16] predicted that vancomycin was unlikely to cause a clinically meaningful reduction in time to defervescence, which was defined as 1.5 days. On the other hand, the between-group difference in mortality rate might have become statistically significant if more patients had been enrolled.
We met our target enrollment. Clinical success rates in the ITT population (linezolid group, 87%; vancomycin group, 85%) were not less than the 80% cure rate assumed for our power calculation. Times to and rates of defervescence appeared to be better in other studies [16] [17] [18] , possibly because we defined defervescence as a temperature of р37.5ЊC, not !38.0ЊC, for 3 days and reported mean, not median, values. Median time to defervescence was 5.0 days in our ITT analysis of both groups, which more closely approximated the values reported by Cometta et al. [16] than did our mean values. Importantly, mortality rates (5.6% and 7.6% for linezolid and vancomycin, respectively) were similar to those in other studies (5%-10%) [16] [17] [18] .
Although the overall microbiologic success rate by patient was similar between groups, the eradication rate favored linezolid for enterococci (9 [90%] of 10 patients vs. 3 [23%] of 11 patients) and became significant for E. faecium ( ) . P p .02 In addition, vancomycin-resistant enterococci were isolated during therapy in 2 vancomycin-treated patients. Linezolid resistance was not observed. These findings should be interpreted with caution because of the small number of pathogens.
Our study demonstrated faster defervescence for linezolid than for vancomycin in patients infected with demonstrated gram-positive pathogens, accompanied by a transiently delayed absolute neutrophil count recovery that did not affect the mean duration of treatment. Although linezolid was reported to be associated with neutropenia in case reports [19] [20] [21] , drug ther- apy did not appear to be responsible for the time-dependent associations in figure 2 , because times to defervescence and absolute neutrophil count recovery were similar between groups for patients with fever of uncertain origin. The paradox of faster defervescence with delayed absolute neutrophil count recovery may be attributable to physiological processes during recovery from acute bacterial infection. During the early convalescent phase, neutrophil egress from bone marrow decreases [22] . In addition, leukocytes integrate chemoattractant signals while rolling along the vascular endothelial surface, until they reach a critical activation level and then adhere at the inflammation site [23] . Therefore, decreased peripheral absolute neutrophil count may reflect delivery to the infection site, where neutrophils perform host defense activities. Collectively, these processes could explain why delayed absolute neutrophil count recovery in the linezolid group did not interfere with recovery from bacterial infection. In fact, one could postulate enhanced chemoattraction to the infection site, thereby accounting for transient peripheral neutropenia in patients with documented bacterial infection.
Laboratory findings confirmed profound myelosuppression at enrollment and gradual improvement during treatment, but there were no between-group differences in platelet count or in other hematologic variables except for the aforementioned transient absolute neutrophil count effects. In a dedicated analysis of hematologic effects [24] , linezolid did not affect mean platelet counts, absolute or cumulative incidence of low counts, changes from baseline levels, or bleeding complications in randomized comparisons with vancomycin in patients with nosocomial pneumonia.
Both linezolid and vancomycin appeared to be well tolerated, as determined on the basis of the low incidence of treatment discontinuations associated with adverse events. Adverse events were similar to those in the phase III program [25] . Linezolid appeared to have a safety advantage based on the incidence of drug-related adverse events, drug-related episodes of renal failure, and all-causality episodes of renal failure.
We did not control use of antibiotics with activity against gram-negative bacteria, fungi, or viruses, but we confirmed absence of between-group differences. Furthermore, clinical success rates were similar after we excluded patients who received potentially effective antibiotics for intercurrent illness or who received antifungal or antiviral drugs (data not shown).
In conclusion, there is no clear gold standard for treatment of febrile neutropenic patients with cancer and gram-positive bacterial infections. In this study, efficacy was generally similar in linezolid-and vancomycin-treated patients. The defervescence advantage in the MITT and microbiologically evaluable subsets, coupled with transiently delayed absolute neutrophil count recovery, merits further analysis, to determine the kinetics and mechanism of linezolid's effect in patients with bacterial infection. Linezolid was well tolerated, with safety in these patients similar to that in other populations, and treatment did not appear to have negative effects on platelet recovery, a concern in this high-risk population. Linezolid appears to offer a useful option for febrile neutropenic patients with cancer who are candidates for vancomycin therapy, especially if resistance is suspected or documented.
